High-Affinity Niacin Receptor GPR109A Agonists
Annual Reports in Medicinal Chemistry, ISSN: 0065-7743, Vol: 45, Issue: C, Page: 72-94
2010
- 9Citations
- 15Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
This chapter focuses on high-affinity niacin receptor GPR109A Agonists. Niacin (nicotinic acid) at high doses favorably modulates the human lipid profile by elevating high-density lipoprotein cholesterol (HDL-C) and decreasing low-density lipoprotein cholesterol (LDL-C) and lipoprotein a [Lp(a)]. Specifically, the ability of niacin to increase HDL-C (∼20%) is greater than any other drug in the market. As such niacin is considered a broad-spectrum lipid-lowering drug. With well-established animal models to evaluate vasodilation and free fatty acids (FFA) reduction, several compounds have been profiled in vivo and they indeed displayed improved TIs relative to niacin. In addition, these models appeared to correlate to humans as two candidates including both MK-0354 and INCB-19062 that showed excellent FFA reduction accompanied by minimal flushing in humans. It is conceivable that GPR109A is still involved in the vascular inflammation pathway related to the antiatherosclerotic effect of niacin. To further investigate the therapeutic potential of GPR109A agonists in cardiovascular diseases or metabolic disorders, it is necessary to further elucidate the mechanism of action of niacin and the pharmacology of GPR109A.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0065774310450058; http://dx.doi.org/10.1016/s0065-7743(10)45005-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77957806526&origin=inward; https://linkinghub.elsevier.com/retrieve/pii/S0065774310450058; http://linkinghub.elsevier.com/retrieve/pii/S0065774310450058; http://dx.doi.org/10.1016/s0065-7743%2810%2945005-8; https://dx.doi.org/10.1016/s0065-7743%2810%2945005-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know